Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2019

View Archived Issues

Flesh-eating bacteria definitely not better together

BRN4/BRN2 TFs released in prostate cancer-derived EVs drive neuroendocrine differentiation in NEPC

AbbVie constructs anti-TNF-alpha antibody-steroid antibody-drug conjugate for rheumatoid arthritis

Pfizer presents early clinical data for PF-06865571 and PF-05221304

Phase I data reported for DNA vaccine GLS-6150 in patients with chronic HCV infection

Recessive mutations in BSN identified as potential new cause of SRNS

Osteoclast precursor macrophages are potential RA therapeutic targets

European Commission approves Rhokiinsa

FDA clears IND application for phase I study of BP-1002

First-in-human study of AZD-2693

Pfizer initiates first-in-human study of PF-07038124

Positive preclinical data reported for leronlimab in humanized mouse model of NAFLD

ALG-055009: a THR-beta agonist for treating NASH

Phase II data on AG-10 in ATTR cardiomyopathy support entry into phase III

First-in-human trial with the triple gene construct INXN-4001 for treatment of heart failure

CtBP2 affects multiple pathways in acute kidney injury

New cannabinoid receptor modulators revealed in recent patent

University of Texas System discloses PTPN11 inhibitors

Incyte discloses adenosine A2A and A2B receptor antagonists

Chinese researchers identify BRD4 inhibitors

New compounds for cancer patented by Hinova Pharmaceuticals

FDA approves Calquence for CLL and SLL

Xcopri wins FDA approval for partial-onset seizures in adults

Aprinoia begins phase II study of tau PET tracer 18F-APN-1607

Inhibiting bradykinin B1 receptor may alleviate hypertensive kidney disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...